1. Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study - development of a clinical nomogram.
- Author
-
Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Kragh Jørgensen RR, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bjørn Poulsen C, Ortved Gang A, Brown P, El-Galaly TC, and Stauffer Larsen T
- Subjects
- Humans, Aged, Male, Female, Aged, 80 and over, Middle Aged, Denmark epidemiology, Prognosis, Registries, Survival Rate, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse blood, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse therapy, Nomograms
- Abstract
The International Prognostic Index (IPI) is the most frequently used tool for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) of all ages. This study validated and compared six models developed for patients above 60 with International Prognostic Indices (IPI, R-IPI, NCCN-IPI). Moreover, we created a clinical nomogram with an online tool for individualized predictions. A total of 2,835 patients aged over 60 with newly diagnosed DLBCL treated with potentially curative immunochemotherapy were identified in the Danish Lymphoma Registry. A nomogram was developed by combining NCCN-IPI variables (excluding extranodal localization), albumin, and platelet levels in 1,970 patients and verified the results in the remaining 956 patients. Compared to other models, the elderly IPI (E-IPI) and age-adjusted IPI (aaIPI) showed better accuracy and discriminatory ability. However, the models failed to identify a high-risk group with a 3-year overall survival rate below 40%. Our nomogram-based model demonstrated superior discriminatory ability and provided more precise individual predictions than all other models based on a risk stratification system. Most clinical prognostic models fail to accurately predict patient outcomes in patients over 60 years old. Therefore, nomogram-based models should be considered in this population to prevent information loss due to variable dichotomization., Competing Interests: Declarations. Competing interests: JJ has received travel support from AstraZeneca and Roche. PB has served on advisory boards for Roche, Abbvie, and SERB. TSL has served on advisory boards/consultancy for Roche, Novartis, Gilead, and BMS. TSL received a research Grant from Genentech and travel support from Roche. Other authors have no relevant financial or non-financial interests to disclose. Ethical approval and consent to participate: This study was performed in accordance with the principles of the Declaration of Helsinki. The Advisory Board for Clinical Quality Development Program (RKKP) (project number 21/27006) has granted approval for conducting this registry-based study, ensuring total anonymity of patients. Further details can be found in the Declaration on passing personal data covered by § 10, a subsection of the Data Protection Act, 1 and 2’, https://www.retsinformation.dk/eli/lta/2019/1509 . Therefore, informed consent from patients was not obtained., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2025
- Full Text
- View/download PDF